RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nuoncology Labs Stock

Nuoncology Labs P/S 2024

Nuoncology Labs P/S

0

Ticker

NLAB

ISIN

US67057T1079

WKN

916415

As of Nov 3, 2024, Nuoncology Labs's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Nuoncology Labs P/S history

Nuoncology Labs Aktienanalyse

What does Nuoncology Labs do?

Nuoncology Labs Inc is a biotechnology company specialized in the development of novel cancer therapies. It was founded in 2015 by experienced scientists and entrepreneurs in the field of biotechnology. The main goal of Nuoncology Labs Inc is to develop better and more effective treatments for cancer. The company relies on innovative technologies and approaches to specifically target and combat cancer cells without damaging healthy tissue. An essential element of Nuoncology Labs Inc's business model is its close collaboration with leading research institutions worldwide. Through these partnerships, the company is able to access the latest knowledge and technologies in cancer research and utilize them for its own development of therapy approaches. Nuoncology Labs Inc is divided into various divisions, each focusing on specific aspects of cancer research and treatment. One important division is the exploration of novel drug candidates that target specific types and stages of cancer. The company utilizes state-of-the-art drug screening technology to identify and optimize promising candidates. Another division of Nuoncology Labs Inc focuses on the development of innovative diagnostic tools for cancer early detection and diagnosis. These tools incorporate advanced technologies such as liquid biopsy and imaging techniques to detect tumor cells and DNA alterations in the blood. Furthermore, a central focus of Nuoncology Labs Inc is the development of targeted therapies that aim at specific signaling pathways in cancer cells. The company utilizes antibodies and other targeted agents that target specific receptors or proteins in the cancer cells. An additional important product of Nuoncology Labs Inc is an innovative therapy system for immuno-oncology. This method aims to activate the body's own immune system specifically against cancer cells. The therapy concept is based on the application of specially designed immune stimulators that encourage the immune system to more effectively combat cancer cells. Overall, Nuoncology Labs Inc is one of the most promising companies in the field of biotechnology and cancer research. The company aims to develop innovative therapy approaches that can contribute to making cancer treatment more effective and tolerable. Nuoncology Labs Inc works closely with leading research institutions worldwide and utilizes state-of-the-art biotechnology technologies and methods. Nuoncology Labs ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Nuoncology Labs's P/S Ratio

Nuoncology Labs's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Nuoncology Labs's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Nuoncology Labs's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Nuoncology Labs’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Nuoncology Labs stock

What is the price-to-earnings ratio of Nuoncology Labs?

The price-earnings ratio of Nuoncology Labs is currently 0.

How has the price-earnings ratio of Nuoncology Labs changed compared to last year?

The price-to-earnings ratio of Nuoncology Labs has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Nuoncology Labs high compared to other companies?

Yes, the price-to-earnings ratio of Nuoncology Labs is high compared to other companies.

How does an increase in the price-earnings ratio of Nuoncology Labs affect the company?

An increase in the price-earnings ratio of Nuoncology Labs would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Nuoncology Labs affect the company?

A decrease in the price-earnings ratio of Nuoncology Labs would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Nuoncology Labs?

Some factors that influence the price-earnings ratio of Nuoncology Labs are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Nuoncology Labs pay?

Over the past 12 months, Nuoncology Labs paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nuoncology Labs is expected to pay a dividend of 0 USD.

What is the dividend yield of Nuoncology Labs?

The current dividend yield of Nuoncology Labs is .

When does Nuoncology Labs pay dividends?

Nuoncology Labs pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nuoncology Labs?

Nuoncology Labs paid dividends every year for the past 0 years.

What is the dividend of Nuoncology Labs?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nuoncology Labs located?

Nuoncology Labs is assigned to the '-' sector.

Wann musste ich die Aktien von Nuoncology Labs kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nuoncology Labs from 11/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/3/2024.

When did Nuoncology Labs pay the last dividend?

The last dividend was paid out on 11/3/2024.

What was the dividend of Nuoncology Labs in the year 2023?

In the year 2023, Nuoncology Labs distributed 0 USD as dividends.

In which currency does Nuoncology Labs pay out the dividend?

The dividends of Nuoncology Labs are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nuoncology Labs

Our stock analysis for Nuoncology Labs Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nuoncology Labs Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.